A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants

Phase 1 Completed 58 enrolled Eli Lilly and Company

RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to compare a study drug known as Insulin glargine with Lantus in healthy Chinese participants. Blood samples will be taken to compare how the body handles the drugs and how they affect blood sugar levels. Side effects and tolerability will be documented. The study will last at least 18 days, not including screening. Screening is required within 4 weeks prior to the start of the study.

Timeline

Start: 2018-09-26
Primary completion: 2019-11-04
Completion: 2019-11-04

Publications

Liu H, Wang F, Ji Y, Ma T, Li H, Linnebjerg H, Chua L, Tham LS, Yu Y. A Euglycemic Glucose Clamp Study to Evaluate the Bioavailability of LY2963016 Relative to Insulin Glargine in Healthy Chinese Subjects. Clin Pharmacol Drug Dev. 2021 Dec;10(12):1452-1459. doi: 10.1002/cpdd.1014. Epub 2021 Aug 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	insulin glargine	Protein / enzyme biologic	0.5 iu/kg	Subcutaneous

Indications

No indication recorded.